Transplant Immunobiology: Many Answers Raising Even More Questions.

The authors found that HSCT recipients of grafts carrying the -1082GG interleukin-10 (IL-10) gene promoter region variant had a three-fold lower incidence of grade II-IV acute GVHD compared to IL-10 -1082AA graft recipients. Immunologic complications following organ, cell, or tissue transplantation still raise significant challenges related to their diagnosis and treatment. The pre-transplant crossmatch test between donor cells and recipient sera developed by Terasaki in the mid-1960s has allowed for better organ allocation and reduced immunologic risks after transplantation at a time when immunosuppressive medication was in its infancy. In spite of an increased understanding of transplant immunobiology and the availability of effective immunosuppression, acute rejection or graft-versus-host disease (GVHD) still occur in up to 50% of transplant recipients, depending on the graft type [[1]]. [Extracted from the article]